Cash, Cash Equivalents, and Short-term Investments of Syros Pharmaceuticals, Inc. from 31 Dec 2016 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.
Summary
Syros Pharmaceuticals, Inc. quarterly Cash, Cash Equivalents, and Short-term Investments in USD history and change rate from 31 Dec 2016 to 31 Mar 2024.
  • Syros Pharmaceuticals, Inc. Cash, Cash Equivalents, and Short-term Investments for the quarter ending 31 Mar 2024 was $108,300,000.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, and Short-term Investments, Quarterly (USD)
Cash, Cash Equivalents, and Short-term Investments, YoY Quarterly Change (%)

Syros Pharmaceuticals, Inc. Quarterly Cash, Cash Equivalents, and Short-term Investments (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $108,300,000 31 Mar 2024 10-Q 14 May 2024 2024 Q1
Q4 2020 $174,000,000 +$82,600,000 +90% 31 Dec 2020 10-K 04 Mar 2021 2020 FY
Q1 2020 $121,900,000 +$46,000,000 +61% 31 Mar 2020 10-Q 07 May 2020 2020 Q1
Q4 2019 $91,400,000 -$8,300,000 -8.3% 31 Dec 2019 10-K 05 Mar 2020 2019 FY
Q3 2019 $108,100,000 -$5,131,000 -4.5% 30 Sep 2019 10-Q 12 Nov 2019 2019 Q3
Q2 2019 $121,700,000 -$2,666,000 -2.1% 30 Jun 2019 10-Q 01 Aug 2019 2019 Q2
Q1 2019 $75,900,000 -$45,841,000 -38% 31 Mar 2019 10-Q 01 May 2019 2019 Q1
Q4 2018 $99,700,000 +$27,651,000 +38% 31 Dec 2018 10-K 07 Mar 2019 2018 FY
Q3 2018 $113,231,000 +$31,283,000 +38% 30 Sep 2018 10-Q 01 Nov 2018 2018 Q3
Q2 2018 $124,366,000 +$32,845,000 +36% 30 Jun 2018 10-Q 07 Aug 2018 2018 Q2
Q1 2018 $121,741,000 +$51,247,000 +73% 31 Mar 2018 10-Q 10 May 2018 2018 Q1
Q4 2017 $72,049,000 -$11,544,000 -14% 31 Dec 2017 10-Q 01 Nov 2018 2018 Q3
Q3 2017 $81,948,000 30 Sep 2017 10-Q 08 Nov 2017 2017 Q3
Q2 2017 $91,521,000 30 Jun 2017 10-Q 09 Aug 2017 2017 Q2
Q1 2017 $70,494,000 31 Mar 2017 10-Q 15 May 2017 2017 Q1
Q4 2016 $83,593,000 31 Dec 2016 10-K 12 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.